CSL

Immune-mediated diseases affect millions globally, with many patients requiring more effective and targeted therapies.

CSL has licensed a Monash University-developed antibody therapeutic program targeting these conditions, following a collaboration through the CSL Research Acceleration Initiative.

Originating from the laboratory of Associate Professor Remy Robert, the program progressed from academic research to commercial licensing in December 2025.